Section Arrow
MRUS.NASDAQ
- Merus NV
Quotes are at least 15-min delayed:2024/11/10 17:06 EST
Last
 54.5
0 (0.00%)
Day High 
54.9 
Prev. Close
54.5 
1-M High
55.39 
Volume 
340.27K 
Bid
21.74
Ask
54.54
Day Low
53.5 
Open
54.54 
1-M Low
48.42 
Market Cap 
3.72B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 51.99 
20-SMA 52.15 
50-SMA 50.91 
52-W High 61.61 
52-W Low 22.01 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.89/-3.75
Enterprise Value
3.73B
Balance Sheet
Book Value Per Share
10.95
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
43.95M
Operating Revenue Per Share
0.67
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.0189+0.001+5.59%-- 
IOVAIovance Biotherapeutics10.585-1.695-13.80%-- 
SGMOSangamo Therapeutics2.87+0.06+2.14%-- 
ARDXArdelyx5.07-1.31-20.53%-- 
MRNAModerna46.84-3.44-6.84%-- 
Quotes are at least 15-min delayed:2024/11/10 17:06 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.